| Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives | | |
| Effect of Glucagon-like Peptide 1 Receptor Agonists on the Renal Protection in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis | Diabetes and Metabolism | 2022 |
| Molecular Mechanisms and Therapeutic Targets for Diabetic Kidney Disease | Kidney International | 2022 |
| Recent advances in the pharmacotherapeutic management of diabetic kidney disease. | Expert Opinion on Pharmacotherapy | 2022 |
| Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers. | Frontiers in Pharmacology | 2022 |
| Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations. | Diabetes Therapy | 2022 |
| Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities. | Handbook of Experimental Pharmacology | 2022 |
| Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular and Renal Outcomes: A Meta-Analysis and Meta-Regression Analysis. | Diabetes, Obesity and Metabolism | 2022 |
| Clinical relevance of recent outcome trials with antidiabetic drugs | Practical Diabetes | 2021 |
| Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy? | World Journal of Diabetes | 2020 |
| Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular and Renal Outcomes: A Systematic Review, Meta-analysis, and Meta-regression Analysis | | |
| Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury | Clinical Journal of the American Society of Nephrology: CJASN | 2020 |
| Safety of injectable semaglutide for type 2 diabetes | Expert Opinion on Drug Safety | 2020 |
| Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection | Diabetes, Obesity and Metabolism | 2021 |
| Recent developments in GLP-1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class | Diabetes, Obesity and Metabolism | 2021 |
| Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence | Cardiovascular Diabetology | 2021 |
| Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide | Frontiers in Endocrinology | 2021 |
| Chronic kidney disease detection, staging and treatment in cardiovascular disease prevention | Heart | 2021 |
| Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis | Cardiovascular Diabetology | 2021 |
| The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes | Diabetes Therapy | 2020 |
| Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients | Postgraduate Medicine | 2020 |
| Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies | Diabetes Therapy | 2020 |
| Renal protection with glucagon-like peptide-1 receptor agonists | Current Opinion in Pharmacology | 2020 |
| Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE | Diabetic Medicine | 2020 |
| Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL | Diabetes, Obesity and Metabolism | 2020 |
| Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial | Cardiovascular Diabetology | 2019 |
